A study involving 41 patients with type 2 diabetes and rheumatoid arthritis revealed that the use of anakinra, a human interleukin-1 receptor antagonist, led to a progressive A1C reduction, compared with a tumor necrosis factor inhibitor. Published in PLOS Medicine, researchers found that the anakinra group also experienced progressive reductions in fasting plasma glucose over three and six months, compared with the TNFi group.
Diabetes, rheumatoid arthritis patients may benefit from IL-1 inhibition
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.